Phase II Study of Erdafitinib in Patients With Tumors With < em > FGFR < /em > Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1

CONCLUSION: Erdafitinib did not meet its primary end point of efficacy as determined by ORR in treatment-refractory solid tumors harboring FGFR1-4 amplifications. Our findings support that rearrangements and gene mutations, but not amplifications, of FGFR remain the established FGFR alterations with approved indications for FGFR inhibition.PMID:38603651 | DOI:10.1200/PO.23.00406

Source: Ann Oncol - April 11, 2024 Category: Cancer & Oncology Authors: Jun Gong Alain C Mita Zihan Wei Heather H Cheng Edith P Mitchell John J Wright S Percy Ivy Victoria Wang Robert C Gray Lisa M McShane Larry V Rubinstein David R Patton P Mickey Williams Stanley R Hamilton Ajjai S Alva James V Tricoli Barbara A Conley Carl Source Type: research